In short
This article explores the clinical trials of EO2463, an innovative cancer vaccine therapy being studied for the treatment of indolent Non-Hodgkin's Lymphoma, specifically Follicular Lymphoma and Marginal Zone Lymphoma. The trials aim to evaluate the safety, efficacy, and potential combinations of EO2463 with other treatments in both newly diagnosed and previously treated patients.
At a glance
- Drug Name
- EO2463
- Drug Type
- Novel microbial-derived peptide therapeutic vaccine
- Target Condition
- Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
- Trial Phase
- Phase 1/2
- Administration
- Subcutaneous injection
- Combinations Studied
- EO2463 alone, with lenalidomide, with rituximab, and with both lenalidomide and rituximab
- Primary Objectives
- Determine safe dose, assess safety in combinations, evaluate objective response rate
- Key Eligibility Criteria
- Adults with FL or MZL, HLA-A2 positive, varying disease status based on cohort
- Study Duration
- 9-12 months active treatment, followed by short-term and long-term follow-up
What is EO2463?
EO2463 is a new type of cancer treatment called a microbial-derived peptide therapeutic vaccine. It is currently being studied for the treatment of certain types of indolent Non-Hodgkin's Lymphoma (NHL), which are slow-growing blood cancers affecting the lymphatic system. This innovative therapy is designed to stimulate the immune system to fight cancer cells.
Target Conditions
EO2463 is being investigated for the treatment of two specific types of indolent Non-Hodgkin's Lymphoma:
- Follicular Lymphoma (FL): A common type of slow-growing lymphoma that develops from B-lymphocytes (B-cells).
- Marginal Zone Lymphoma (MZL): A group of lymphomas that also develop from B-cells. This includes three subtypes:
- Extranodal MZL (EMZL, also known as MALT lymphoma)
- Splenic MZL (SMZL)
- Nodal MZL (NMZL)
These lymphomas are considered "indolent" because they tend to grow and spread slowly compared to more aggressive forms of lymphoma.
How EO2463 Works
EO2463 is composed of several peptides (small protein fragments) derived from microbes. These peptides are:
- OMP72
- OMP64
- OMP65
- OMP66
- UCP2
These peptides are designed to stimulate the patient's immune system, particularly T-cells, to recognize and attack cancer cells. The vaccine works by training the immune system to identify specific proteins (antigens) found on B-cells, including CD20, CD22, CD37, and BAFF-receptor.
Clinical Trial Overview
EO2463 is currently being studied in a global, multicenter Phase 1/2 clinical trial. The trial is investigating the use of EO2463 in several ways:
- As a standalone treatment (monotherapy)
- In combination with lenalidomide (a medication that modifies the immune system)
- In combination with rituximab (an antibody therapy that targets B-cells)
- In combination with both lenalidomide and rituximab
The trial is divided into two main phases:
Phase 1: This phase aims to determine the safe and recommended dose of EO2463 for further study. It will also assess the safety of combining EO2463 with other treatments.
Phase 2: This phase will evaluate how well EO2463 works in treating indolent NHL by measuring the objective response rate (ORR). The ORR is the percentage of patients whose cancer shrinks or disappears after treatment.
Potential Benefits
While the effectiveness of EO2463 is still being studied, the researchers hope to see several potential benefits, including:
- Improved response rates for patients with indolent NHL
- Longer-lasting responses to treatment
- Delayed need for additional cancer treatments
- Improved progression-free survival (time without cancer growth)
- Better overall survival rates
The trial will also look at how EO2463 affects various immune cells and antibodies in the body, which could provide valuable information about how the treatment works.
Eligibility Criteria
The trial has specific criteria for who can participate. Some key eligibility factors include:
- Age 18 or older
- Diagnosed with follicular lymphoma or marginal zone lymphoma
- HLA-A2 positive (a specific genetic marker)
- Measurable disease (tumors that can be assessed)
- Varying requirements for prior treatments, depending on the study group
There are also several factors that may exclude someone from participating, such as certain medical conditions or previous treatments. It's important to discuss eligibility with a healthcare provider.
Safety Considerations
As with any new treatment, safety is a primary concern. The trial will closely monitor participants for side effects and adverse events. Some specific safety measures include:
- Regular check-ups and laboratory tests
- Monitoring of immune system changes
- Strict guidelines for pregnancy prevention due to potential risks associated with some of the combination treatments
- Long-term follow-up to assess any delayed effects of treatment
It's important to note that as an experimental treatment, not all potential risks of EO2463 are known. Patients considering participation in the trial should discuss the potential risks and benefits thoroughly with their healthcare team.